The global market for vitamin D therapy was valued at US$ 1,919.4 million in 2018 and is expected to hit US$ 4,721.9 million by 2027, increasing to CAGR by 10.6 per cent from 2019 to 2027.
Osteoporosis is a disease manifested by low bone density, deterioration of bone tissue, and decreased bone strength, which increases the risk of fracture. It is one of the most common causes of mortality in elderly patients and young children suffering with malnutrition. Risk factors associated with vitamin D deficiency include ageing, low dietary intake of calcium, genetic predisposition, decreased physical activity and abnormal thyroid function.
The oral route of administration is dominated by the market for vitamin D therapy. It has garnered immense popularity among children due to ease of administration and has been formulated in different sizes and colours to increase its external appearance and to increase the palatability of sugar coating. The parenteral route of administration is superior due to its excellent pharmacokinetic and pharmacodynamic drug profile and useful in elderly people with impaired absorption of vitamin D via the gastrointestinal tract.
Osteoporosis is currently the application segment of the market for vitamin D therapy. According to the International Osteoporosis Foundation (IOF) research studies, 1 in 3 women and 1 in 5 men above 50 years of age will suffer from an osteoporotic fracture at least once in their lifetime. Malnutrition and depletion of calcium and vitamin D I daily dietary intake has resulted in a significant increase in rickets in young children in developing and poor countries. In the last 2 decades, skin disease are on a rise owing to depletion of ozone layers has exposed the skin surface to harmful UV radiation, thereby depleting keratinocytes used in vitamin D synthesis, hence causing inflammatory skin diseases such as atopic dermatitis and psoriasis.
North America currently holds 33% of the regional market share for vitamin D therapy. The prime factors contributing to the dominance of North America are rising prevalence of osteoporosis and low bone mass & increasing public health awareness regarding vitamin D deficiency. Europe is the second-largest market with a 30 per cent share due to the increasing prevalence of skin disorders associated with low serum cholecalciferol levels.
The Asia Pacific holds 20% market share and is willing to capture the market in the near future on account of significant rise in malnourishment in young children resulting in rickets and domicile of key players such as Cadila Healthcare, Alkem Laboratories, Torrent Pharmaceuticals Ltd., etc. drive the market growth in the region.